Market revenue in 2024 | USD 34,289.6 million |
Market revenue in 2030 | USD 50,997.9 million |
Growth rate | 6.8% (CAGR from 2025 to 2030) |
Largest segment | Conventional drugs (small molecules) |
Fastest growing segment | Biologics & Biosimilars (Large Molecules) |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Biologics & Biosimilars (Large Molecules), Conventional Drugs (Small Molecules) |
Key market players worldwide | Merck & Co Inc, Roche Holding AG, Novartis AG ADR, AbbVie Inc, Johnson & Johnson, Pfizer Inc, Bristol-Myers Squibb Co, Sanofi SA, GSK PLC, Takeda Pharmaceutical Co Ltd |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pharmaceutical market will help companies and investors design strategic landscapes.
Conventional drugs (small molecules) was the largest segment with a revenue share of 57.97% in 2024. Horizon Databook has segmented the Australia pharmaceutical market based on biologics & biosimilars (large molecules), conventional drugs (small molecules) covering the revenue growth of each sub-segment from 2018 to 2030.
Australia’s pharmaceutical market is driven by a combination of strong government support, a growing aging population, rising chronic disease prevalence, and a robust research and development (R&D) ecosystem.
These factors, along with the country’s increasing demand for innovative medicines and generics, make Australia an attractive destination for pharmaceutical investments. A key driver of Australia’s pharmaceutical market is its universal healthcare system, Medicare, which ensures affordable access to essential medicines.
The Pharmaceutical Benefits Scheme (PBS) plays a crucial role by subsidizing prescription drugs, making treatments more accessible and reducing out-ofpocket expenses for patients. This system fosters a stable demand for pharmaceuticals, particularly for chronic disease management and elderly care.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia pharmaceutical market , including forecasts for subscribers. This country databook contains high-level insights into Australia pharmaceutical market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related industry reports found.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account